Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada

MT Newswires Live

07/09

Teva Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.

Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.

Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.

Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2650992439"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650992439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650992439?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650992439","market":"nz","top_or_hot":-1,"title":"Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.</p><p>Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.</p><p>Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.</p><p>Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-09 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.</p><p>Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.</p><p>Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.</p><p>Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IEMG","symbol_name":"iShares Core MSCI Emerging Markets ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650992439","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650992439","pubTimestamp":1783600660,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.Sams","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IEMG":"iShares Core MSCI Emerging Markets ETF","BK4581":"高盛持仓","BK4585":"ETF&股票定投概念","BK4504":"桥水持仓","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4596":"哈里斯概念","BK4007":"制药","BK4559":"巴菲特持仓","BK4584":"避孕概念","BK4566":"资本集团","BK4588":"碎股","TEVA":"梯瓦制药","BK4550":"红杉资本持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4557":"大麻股","EMXC":"iShares MSCI Emerging Markets ex China ETF"},"translate_title":"梯瓦与三星Bioepis合作在加拿大商业化Eylea生物仿制药Opuviz","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IEMG":1.5,"TEVA":1,"EMXC":1.5},"content_text":"Teva Pharmaceutical Industries (TEVA) said Thursday it has signed a license and commercialization agreement with Samsung Bioepis for Opuviz, an aflibercept biosimilar referencing Eylea, in Canada.Samsung Bioepis will handle product registration and manufacturing, while Teva Canada will lead commercialization.Opuviz was approved by Health Canada in October 2025 for several eye conditions, including wet age-related macular degeneration and diabetic macular edema.Teva said the deal strengthens its biosimilars portfolio in Canada and expands its ophthalmology presence.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}